International law firm Reed Smith has advised Sixth Element Capital (6EC) and Cancer Research Technology (CRT) on the launch of the CRT Pioneer Fund, a ground-breaking £50m investment fund to bridge the funding gap in the U.K. between cancer drug discovery and early development. The CRT Pioneer Fund, in which CRT and the European Investment Fund (EIF) are the principal investors, will advance potential oncology drugs from discovery through to entry to mid-stage Phase II clinical trials.

Reed Smith acted as sole legal counsel on the establishment of the Fund. The team was led by John Wilkinson and Oliver s'Jacob, partners in our life sciences and investment funds teams respectively, with support from associates Ian Buckley and Rhianydd Griffith. Tax partner Caspar Fox provided tax advice to 6EC and CRT, while funds partner Dale Gabbert also assisted with the fund structuring.

Scottish law firm Brodies advised alongside Reed Smith in relation to the establishment of the Scottish limited partnership set up by the members of 6EC to channel their investment into the Fund.

For a full presentation on the fund please visit YouTube. 

ENDS

Note to Editors:
About Reed Smith
Reed Smith is a global law firm, with 23 offices and more than 1,600 lawyers in offices across Europe, the Middle East, Asia and the United States.
For further information please visit www.reedsmith.com or contact Jeyda Star on +44 (0)20 3116 2571.